Ongoing

This trial will evaluate the effects of EryDex in patients with A-T.

The Platform is a patient-driven effort through which data about people with A-T are shared with researchers.

This study seeks to establish the natural history of pulmonary function decline in the A-T population.

Goals of this study are to develop non-invasive markers that will lessen the impact of swallowing dysfunction.

IntraBio, Inc. is studying the effects of N-Acetyl-L-Leucine on A-T.

This study seeks to develop sensitive, automated and objective means of measuring neurological disease severity.